In a filing, Denali Therapeutics Inc revealed its Chief Medical Officer Ho Carole unloaded Company’s shares for reported $0.25 million on Jan 06 ’25. In the deal valued at $20.22 per share,12,255 shares were sold. As a result of this transaction, Ho Carole now holds 178,580 shares worth roughly $2.71 million.
Then, Ho Carole sold 2,907 shares, generating $60,495 in total proceeds. Upon selling the shares at $20.81, the Chief Medical Officer now owns 175,673 shares.
Before that, Schuth Alexander O. sold 12,255 shares. Denali Therapeutics Inc shares valued at $247,796 were divested by the COFO and Secretary at a price of $20.22 per share. As a result of the transaction, Schuth Alexander O. now holds 247,215 shares, worth roughly $3.76 million.
Deutsche Bank initiated its Denali Therapeutics Inc [DNLI] rating to a Buy in a research note published on February 11, 2025; the price target was $31. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in early January with a ‘”an Outperform”‘ rating. William Blair began covering DNLI with “an Outperform” recommendation on January 03, 2025. Stifel revised its rating on December 16, 2024. It rated DNLI as “a Buy” which previously was an “a Hold”.
Price Performance Review of DNLI
On Monday, Denali Therapeutics Inc [NASDAQ:DNLI] saw its stock fall -8.21% to $15.20. Over the last five days, the stock has lost -26.46%. Denali Therapeutics Inc shares have fallen nearly -25.42% since the year began. Nevertheless, the stocks have fallen -24.79% over the past one year. While a 52-week high of $33.33 was reached on 02/05/25, a 52-week low of $14.56 was recorded on 03/03/25. SMA at 50 days reached $21.22, while 200 days put it at $23.69.
Levels Of Support And Resistance For DNLI Stock
The 24-hour chart illustrates a support level at 14.61, which if violated will result in even more drops to 14.03. On the upside, there is a resistance level at 16.28. A further resistance level may holdings at 17.37. The Relative Strength Index (RSI) on the 14-day chart is 22.53, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.18, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.83%. Stochastics %K at 3.06% indicates the stock is a buying.
